PetIQ Inc (NASDAQ:PETQ) insider Will Santana sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $27.14, for a total value of $542,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:PETQ traded up $0.12 during trading hours on Monday, reaching $27.24. 263,900 shares of the stock were exchanged, compared to its average volume of 359,819. The company has a quick ratio of 1.09, a current ratio of 2.35 and a debt-to-equity ratio of 0.69. PetIQ Inc has a twelve month low of $17.03 and a twelve month high of $29.55. The stock has a market capitalization of $665.34 million and a price-to-earnings ratio of 69.85.

PetIQ (NASDAQ:PETQ) last released its quarterly earnings results on Tuesday, May 15th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.04. PetIQ had a return on equity of 11.39% and a net margin of 0.17%. The company had revenue of $115.10 million for the quarter, compared to analysts’ expectations of $108.54 million. The firm’s revenue for the quarter was up 71.8% compared to the same quarter last year. sell-side analysts expect that PetIQ Inc will post 0.78 EPS for the current fiscal year.

A number of research analysts recently commented on PETQ shares. Zacks Investment Research upgraded PetIQ from a “sell” rating to a “hold” rating in a report on Wednesday, April 18th. BidaskClub cut PetIQ from a “hold” rating to a “sell” rating in a research note on Friday, May 4th. Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of PetIQ in a research note on Wednesday, May 16th. Finally, ValuEngine upgraded PetIQ from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.33.

A number of large investors have recently added to or reduced their stakes in the business. Gamco Investors INC. ET AL acquired a new position in PetIQ during the second quarter worth $806,000. Gabelli Funds LLC lifted its stake in PetIQ by 60.7% during the second quarter. Gabelli Funds LLC now owns 112,500 shares of the company’s stock worth $3,022,000 after purchasing an additional 42,500 shares in the last quarter. Great West Life Assurance Co. Can acquired a new position in PetIQ during the second quarter worth $2,414,000. BlackRock Inc. lifted its stake in PetIQ by 5.5% during the second quarter. BlackRock Inc. now owns 835,035 shares of the company’s stock worth $22,427,000 after purchasing an additional 43,693 shares in the last quarter. Finally, Royce & Associates LP acquired a new position in PetIQ during the second quarter worth $672,000. Institutional investors own 79.77% of the company’s stock.

About PetIQ

PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

Further Reading: Diversification in Investing

Insider Buying and Selling by Quarter for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.